Mutations of proto-oncogenes, i.e., c-myc, RAS family genes (KRAS, HRAS, NRAS, ERB-B, BRAF, HER-2, c-KIT, BCL-2, STAT3), tumour suppressor genes called anti-oncogenes (RB1, P53, PTEN, CDKN2A, INK4), and genes controlling the pro-inflammatory tumour microenvironment, are also commonly observed in the course of cancers in this region [3,15]. This evidence concerns the gene CDKN2A and cancer.